---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-302915"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:23:28.285610+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix reports positive Phase 1 data for BTK degrader NX-2127; 33% ORR in heavily pretreated CLL

## Summary
- ORR of 33% (95% CI 12-62%) in 23 CLL patients who failed median 5 prior therapies, 78% prior BTK+BCL2 inhibitors.
- 48% of CLL patients had BTK resistance mutations; NX-2127 showed activity regardless of mutational status.
- Median follow-up 5.6 months; 14 of 23 CLL patients remained on treatment as of Sept 21, 2022 data cut.
- BTK mutations resistant to covalent and non-covalent inhibitors remained susceptible to degradation by NX-2127.
- Safety profile consistent with prior Phase 1a results and BTK-targeted therapies in heavily pretreated patients.

## SEC filing metadata
- accession: 0001193125-22-302915
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000119312522302915/0001193125-22-302915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000119312522302915/d411325d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-302915
- JSON: https://secwatch.observer/filing/0001193125-22-302915.json
- Plain text: https://secwatch.observer/filing/0001193125-22-302915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.